Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 128 of 128 entries
Sorted by: Best Match Show Resources per page
The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation.

Musculoskeletal care

McKevitt S, Jinks C, Healey EL, Quicke JG.
PMID: 34245657
Musculoskeletal Care. 2021 Jul 10; doi: 10.1002/msc.1579. Epub 2021 Jul 10.

OBJECTIVE: To investigate the attitudes towards, and beliefs about, physical activity (PA) in older adults with osteoarthritis (OA) and comorbidity to understand experiences and seek ways to improve PA participation.METHODS: Semi-structured interviews with adults aged ≥45, with self-reported OA...

Cite
McKevitt S, Jinks C, Healey EL, et al. The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation. Musculoskeletal Care. 2021;doi: 10.1002/msc.1579.
McKevitt, S., Jinks, C., Healey, E. L., & Quicke, J. G. (2021). The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation. Musculoskeletal care, . https://doi.org/10.1002/msc.1579
McKevitt, Sarah, et al. "The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation." Musculoskeletal care vol. (2021). doi: https://doi.org/10.1002/msc.1579
McKevitt S, Jinks C, Healey EL, Quicke JG. The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation. Musculoskeletal Care. 2021 Jul 10; doi: 10.1002/msc.1579. Epub 2021 Jul 10. PMID: 34245657.
Copy Download .nbib Format: NLM
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.

Brain communications

Yeo T, Probert F, Sealey M, Saldana L, Geraldes R, Höeckner S, Schiffer E, Claridge TDW, Leppert D, DeLuca G, Kuhle J, Palace J, Anthony DC.
PMID: 34755110
Brain Commun. 2021 Oct 12;3(4):fcab240. doi: 10.1093/braincomms/fcab240. eCollection 2021.

Accurate determination of relapses in multiple sclerosis is important for diagnosis, classification of clinical course and therapeutic decision making. The identification of biofluid markers for multiple sclerosis relapses would add to our current diagnostic armamentarium and increase our understanding...

Cite
Yeo T, Probert F, Sealey M, et al. Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Commun. 2021;3(4):fcab240doi: 10.1093/braincomms/fcab240.
Yeo, T., Probert, F., Sealey, M., Saldana, L., Geraldes, R., Höeckner, S., Schiffer, E., Claridge, T. D. W., Leppert, D., DeLuca, G., Kuhle, J., Palace, J., & Anthony, D. C. (2021). Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain communications, 3(4), fcab240. https://doi.org/10.1093/braincomms/fcab240
Yeo, Tianrong, et al. "Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach." Brain communications vol. 3,4 (2021): fcab240. doi: https://doi.org/10.1093/braincomms/fcab240
Yeo T, Probert F, Sealey M, Saldana L, Geraldes R, Höeckner S, Schiffer E, Claridge TDW, Leppert D, DeLuca G, Kuhle J, Palace J, Anthony DC. Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Commun. 2021 Oct 12;3(4):fcab240. doi: 10.1093/braincomms/fcab240. eCollection 2021. PMID: 34755110; PMCID: PMC8568847.
Copy Download .nbib Format: NLM
Glasdegib in newly diagnosed acute myeloid leukemia.

Expert review of anticancer therapy

Sarkaria SM, Heaney ML.
PMID: 33593233
Expert Rev Anticancer Ther. 2021 Jun;21(6):573-581. doi: 10.1080/14737140.2021.1891885. Epub 2021 Feb 25.

INTRODUCTION: Acute myeloid leukemia (AML) is an aggressive blood cancer that proves fatal for the majority of affected individuals. Older patients are particularly vulnerable due to more unfavorable disease biology and diminished ability to tolerate intensive induction chemotherapy (ICT)....

Cite
Sarkaria SM, Heaney ML. Glasdegib in newly diagnosed acute myeloid leukemia. Expert Rev Anticancer Ther. 2021;21(6):573-581doi: 10.1080/14737140.2021.1891885.
Sarkaria, S. M., & Heaney, M. L. (2021). Glasdegib in newly diagnosed acute myeloid leukemia. Expert review of anticancer therapy, 21(6), 573-581. https://doi.org/10.1080/14737140.2021.1891885
Sarkaria, Shawn M, and Heaney, Mark L. "Glasdegib in newly diagnosed acute myeloid leukemia." Expert review of anticancer therapy vol. 21,6 (2021): 573-581. doi: https://doi.org/10.1080/14737140.2021.1891885
Sarkaria SM, Heaney ML. Glasdegib in newly diagnosed acute myeloid leukemia. Expert Rev Anticancer Ther. 2021 Jun;21(6):573-581. doi: 10.1080/14737140.2021.1891885. Epub 2021 Feb 25. PMID: 33593233.
Copy Download .nbib Format: NLM
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Brain communications

Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Leppert D, Kuhle J, Anthony DC.
PMID: 33997784
Brain Commun. 2021 Apr 19;3(2):fcab084. doi: 10.1093/braincomms/fcab084. eCollection 2021.

Eighty-five percent of multiple sclerosis cases begin with a discrete attack termed clinically isolated syndrome, but 37% of clinically isolated syndrome patients do not experience a relapse within 20 years of onset. Thus, the identification of biomarkers able to...

Cite
Probert F, Yeo T, Zhou Y, et al. Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain Commun. 2021;3(2):fcab084doi: 10.1093/braincomms/fcab084.
Probert, F., Yeo, T., Zhou, Y., Sealey, M., Arora, S., Palace, J., Claridge, T. D. W., Hillenbrand, R., Oechtering, J., Leppert, D., Kuhle, J., & Anthony, D. C. (2021). Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain communications, 3(2), fcab084. https://doi.org/10.1093/braincomms/fcab084
Probert, Fay, et al. "Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis." Brain communications vol. 3,2 (2021): fcab084. doi: https://doi.org/10.1093/braincomms/fcab084
Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Leppert D, Kuhle J, Anthony DC. Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain Commun. 2021 Apr 19;3(2):fcab084. doi: 10.1093/braincomms/fcab084. eCollection 2021. PMID: 33997784; PMCID: PMC8111065.
Copy Download .nbib Format: NLM
Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia.

Blood

Warren JT, Cupo RR, Wattanasirakul P, Spencer D, Locke AE, Makaryan V, Bolyard AA, Kelley ML, Kingston NL, Shorter J, Bellanné-Chantelot C, Donadieu J, Dale DC, Link DC.
PMID: 34115842
Blood. 2021 Jun 11; doi: 10.1182/blood.2021010762. Epub 2021 Jun 11.

Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis. Approximately one-third of cases do not have a known genetic cause. Exome sequencing of 104 persons with congenital neutropenia identified heterozygous missense variants of CLPB (caseinolytic peptidase B) in...

Cite
Warren JT, Cupo RR, Wattanasirakul P, et al. Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia. Blood. 2021;doi: 10.1182/blood.2021010762.
Warren, J. T., Cupo, R. R., Wattanasirakul, P., Spencer, D., Locke, A. E., Makaryan, V., Bolyard, A. A., Kelley, M. L., Kingston, N. L., Shorter, J., Bellanné-Chantelot, C., Donadieu, J., Dale, D. C., & Link, D. C. (2021). Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia. Blood, . https://doi.org/10.1182/blood.2021010762
Warren, Julia T, et al. "Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021010762
Warren JT, Cupo RR, Wattanasirakul P, Spencer D, Locke AE, Makaryan V, Bolyard AA, Kelley ML, Kingston NL, Shorter J, Bellanné-Chantelot C, Donadieu J, Dale DC, Link DC. Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia. Blood. 2021 Jun 11; doi: 10.1182/blood.2021010762. Epub 2021 Jun 11. PMID: 34115842.
Copy Download .nbib Format: NLM
Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis.

Musculoskeletal care

Smith RD, McHugh GA, Quicke JG, Dziedzic KS, Healey EL.
PMID: 33683799
Musculoskeletal Care. 2021 Dec;19(4):473-483. doi: 10.1002/msc.1540. Epub 2021 Mar 08.

BACKGROUND: This study assessed the measurement properties of two commonly used self-report physical activity (PA) measures: the International Physical Activity Questionnaire-Short Form (IPAQ-SF) and the Physical Activity Scale for the elderly (PASE) in adults with osteoarthritis.METHODS: Secondary analysis of...

Cite
Smith RD, McHugh GA, Quicke JG, et al. Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal Care. 2021;19(4):473-483doi: 10.1002/msc.1540.
Smith, R. D., McHugh, G. A., Quicke, J. G., Dziedzic, K. S., & Healey, E. L. (2021). Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal care, 19(4), 473-483. https://doi.org/10.1002/msc.1540
Smith, R D, et al. "Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis." Musculoskeletal care vol. 19,4 (2021): 473-483. doi: https://doi.org/10.1002/msc.1540
Smith RD, McHugh GA, Quicke JG, Dziedzic KS, Healey EL. Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal Care. 2021 Dec;19(4):473-483. doi: 10.1002/msc.1540. Epub 2021 Mar 08. PMID: 33683799.
Copy Download .nbib Format: NLM
Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis.

Musculoskeletal care

Smith RD, McHugh GA, Quicke JG, Dziedzic KS, Healey EL.
PMID: 33683799
Musculoskeletal Care. 2021 Mar 08; doi: 10.1002/msc.1540. Epub 2021 Mar 08.

BACKGROUND: This study assessed the measurement properties of two commonly used self-report physical activity (PA) measures: the International Physical Activity Questionnaire-Short Form (IPAQ-SF) and the Physical Activity Scale for the elderly (PASE) in adults with osteoarthritis.METHODS: Secondary analysis of...

Cite
Smith RD, McHugh GA, Quicke JG, et al. Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal Care. 2021;doi: 10.1002/msc.1540.
Smith, R. D., McHugh, G. A., Quicke, J. G., Dziedzic, K. S., & Healey, E. L. (2021). Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal care, . https://doi.org/10.1002/msc.1540
Smith, R D, et al. "Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis." Musculoskeletal care vol. (2021). doi: https://doi.org/10.1002/msc.1540
Smith RD, McHugh GA, Quicke JG, Dziedzic KS, Healey EL. Comparison of reliability, construct validity and responsiveness of the IPAQ-SF and PASE in adults with osteoarthritis. Musculoskeletal Care. 2021 Mar 08; doi: 10.1002/msc.1540. Epub 2021 Mar 08. PMID: 33683799.
Copy Download .nbib Format: NLM
Integrating case-finding and initial management for osteoarthritis, anxiety, and depression into primary care long-term condition reviews: results from the ENHANCE pilot trial.

Family practice

Healey EL, Mallen CD, Chew-Graham CA, Nicholls E, Lewis M, Lawton SA, Finney AG, Tan V, Cooper V, Dziedzic KS, Liddle J, Wathall S, Jinks C.
PMID: 34546341
Fam Pract. 2021 Sep 21; doi: 10.1093/fampra/cmab113. Epub 2021 Sep 21.

BACKGROUND: Multimorbidity is increasingly the norm; however, primary care remains focused on single diseases. Osteoarthritis, anxiety, and depression are frequently comorbid with other long-term conditions (LTCs), but rarely prioritized by clinicians.OBJECTIVES: To test the feasibility of a randomized controlled...

Cite
Healey EL, Mallen CD, Chew-Graham CA, et al. Integrating case-finding and initial management for osteoarthritis, anxiety, and depression into primary care long-term condition reviews: results from the ENHANCE pilot trial. Fam Pract. 2021;doi: 10.1093/fampra/cmab113.
Healey, E. L., Mallen, C. D., Chew-Graham, C. A., Nicholls, E., Lewis, M., Lawton, S. A., Finney, A. G., Tan, V., Cooper, V., Dziedzic, K. S., Liddle, J., Wathall, S., & Jinks, C. (2021). Integrating case-finding and initial management for osteoarthritis, anxiety, and depression into primary care long-term condition reviews: results from the ENHANCE pilot trial. Family practice, . https://doi.org/10.1093/fampra/cmab113
Healey, Emma L, et al. "Integrating case-finding and initial management for osteoarthritis, anxiety, and depression into primary care long-term condition reviews: results from the ENHANCE pilot trial." Family practice vol. (2021). doi: https://doi.org/10.1093/fampra/cmab113
Healey EL, Mallen CD, Chew-Graham CA, Nicholls E, Lewis M, Lawton SA, Finney AG, Tan V, Cooper V, Dziedzic KS, Liddle J, Wathall S, Jinks C. Integrating case-finding and initial management for osteoarthritis, anxiety, and depression into primary care long-term condition reviews: results from the ENHANCE pilot trial. Fam Pract. 2021 Sep 21; doi: 10.1093/fampra/cmab113. Epub 2021 Sep 21. PMID: 34546341.
Copy Download .nbib Format: NLM
Showing 121 to 128 of 128 entries